## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($86.83)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Kempner Capital Management Inc. Sells 27,095 Shares of Zimmer Biomet Holdings, Inc. EV**
- Source: MarketBeat | 20251227T132449 | Neutral | Relevance: 100%
- Kempner Capital Management Inc. has significantly reduced its stake in Zimmer Biomet Holdings, Inc., selling 27,095 shares, which accounts for 46.3% of its previous holding. Following this transaction, the firm now owns 31,401 shares of Zimmer Biomet, valued at approximately $3.09 million, making it the 15th largest position in its portfolio. The medical equipment provider recently reported earnings that slightly beat EPS expectations but missed revenue forecasts, while analysts hold a "Hold" rating with an average target price of $107.50 for the stock.

**2. Voya Investment Management LLC Has $5.36 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251225T130552 | Neutral | Relevance: 100%
- Voya Investment Management LLC reduced its stake in Zimmer Biomet Holdings, Inc. by 18.3% in Q3, now holding 54,362 shares valued at $5.36 million. Despite beating Q3 EPS estimates, the medical equipment provider slightly missed revenue expectations, though quarterly revenue rose 9.6% year-over-year. Analysts currently rate Zimmer Biomet as a "Hold" with an average price target of $107.50, and the company announced a quarterly dividend of $0.24 per share.

**3. Zacks Research Predicts Weaker Earnings for Zimmer Biomet**
- Source: MarketBeat | 20251225T124952 | Neutral | Relevance: 100%
- Zacks Research has revised down its Q2 2026 EPS estimate for Zimmer Biomet to $2.10 and projects FY2026 EPS at $8.16, with FY2027 at $8.84. Despite beating consensus EPS in its last report, the medical equipment provider's revenue slightly missed expectations. Analysts currently hold a "Hold" consensus rating with a $107.50 price target for ZBH.

**4. Zimmer Biomet Holdings, Inc. $ZBH is QSM Asset Management Ltd's Largest Position**
- Source: MarketBeat | 20251226T123227 | Somewhat-Bullish | Relevance: 98%
- QSM Asset Management Ltd significantly increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the third quarter, making it their largest position. The medical equipment provider also reported strong third-quarter earnings, beating analyst EPS estimates and showing a 9.6% year-over-year revenue increase with positive FY 2025 guidance. Institutional investors hold a substantial portion of the company's stock, and Zimmer Biomet recently declared a quarterly dividend.

**5. Robust Growth in Da Vinci Robotic Surgical System Market is Going**
- Source: openPR.com | 20251226T060830 | Somewhat-Bullish | Relevance: 65%
- A new report by Coherent Market Insights projects robust growth for the Da Vinci Robotic Surgical System Market between 2025 and 2032. The report analyzes market trends, growth opportunities, and competition, highlighting key players like Intuitive Surgical, Medtronic, and Siemens Healthineers. It aims to provide critical insights for businesses, investors, and strategists in the healthcare technology sector.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Baird | $100 | $117 | -15% |
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Baird | down | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 7.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Forward P/E 10.7x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.0B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 10.7 |
| Current P/E | 11.1 |
| YoY Growth | 4.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.9% to -1.3% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.3pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Below SMA200 (0.93x), long-term trend not supportive. RSI neutral at 45. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.27% (CS: 38) | Neutral |
| RSI_14 | 44.9 | Neutral |
| MACD Histogram | -0.09 | Bearish |
| vs SMA20 | 0.985x | Below |
| vs SMA50 | 0.962x | Below |
| vs SMA200 | 0.927x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $90.79
- **Stop Loss:** $86.83 (4.4% risk)
- **Target:** $94.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 333
- **Position Value:** $30,233.07
- **Portfolio %:** 30.23%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*